Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000–2013

Arthritis and Rheumatology

Volumn 68, Issue 12, 2016, Pages 3023-3034

  Klotsche, Jens ^a   Raab, Anna ^a   Niewerth, Martina ^b   Sengler, Claudia ^b   Ganser, Gerd ^c   Kallinich, Tilmann ^a   Niehues, Tim ^d   Hufnagel, Markus ^e   Thon, Angelika ^f   Hospach, Toni ^g   Horneff, Gerd ^h   Minden, Kirsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN RHEUMATISM RESEARCH CENTRE BERLIN   (Germany)

^c Abt Kinder und Jugendrheumatologie   (Germany)

^d HELIOS KLINIKUM KREFELD   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g OLGAHOSPITAL   (Germany)

^h Asklepios Clinic Sankt Augustin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANAKINRA; BIOLOGICAL PRODUCT; CANAKINUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TOCILIZUMAB; ANTIRHEUMATIC AGENT;

ADOLESCENT; ARTICLE; CHILD; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE REGISTRY; FEMALE; FUNCTIONAL ASSESSMENT; GERMANY; GROWTH RETARDATION; HUMAN; JUVENILE ARTHRITIS DISEASE ACTIVITY SCORE IN 10 JOINTS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; TREND STUDY; ARTHRITIS, JUVENILE; COMPLICATION; CROSS-SECTIONAL STUDY; FACTUAL DATABASE; GROWTH DISORDERS; INFANT; LONGITUDINAL STUDY; PATHOPHYSIOLOGY; PATIENT-REPORTED OUTCOME; PRESCHOOL CHILD; REGISTER; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; FEMALE; GERMANY; GLUCOCORTICOIDS; GROWTH DISORDERS; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; PATIENT REPORTED OUTCOME MEASURES; REGISTRIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84997848582     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39796     Document Type: Article

References (50)

1. Nigrovic PA. Is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? [review]. Arthritis Rheumatol 2014;66:1405–13.
2. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390–2.
3. Woerner A, von Scheven-Gete A, Cimaz R, Hofer M. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations. Expert Rev Clin Immunol 2015;11:575–88.
4. Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2006;2:28–34.
5. De Benedetti F. Inflammatory cytokines in the pathogenesis and treatment of systemic juvenile idiopathic arthritis: basic science for the clinician. Pediatr Rheumatol Online J 2005;3:122–36.
6. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421–6.
7. Hashkes PJ, Wright BM, Lauer MS, Worley SE, Tang AS, Roettcher PA, et al. Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum 2010;62:599–608.
8. Ramanan AV, Rosenblum ND, Feldman BM, Laxer RM, Schneider R. Favorable outcome in patients with renal involvement complicating macrophage activation syndrome in systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004;31:2068–70.
9. Schneider R, Laxer RM. Systemic onset juvenile rheumatoid arthritis. Baillieres Clin Rheumatol 1998;12:245–71.
10. Bertilsson L, Andersson-Gare B, Fasth A, Forsblad-d'Elia H. A 5-year prospective population-based study of juvenile chronic arthritis: onset, disease process, and outcome. Scand J Rheumatol 2012;41:379–82.
11. Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum 2011;63:2809–18.
12. Raab A, Sengler C, Niewerth M, Klotsche J, Horneff G, Zink A, et al. Comorbidity profiles among adult patients with juvenile idiopathic arthritis: results of a biologic register. Clin Exp Rheumatol 2013;31:796–802.
13. Selvaag AM, Aulie HA, Lilleby V, Flatø B. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis 2016;75:190–5.
14. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385–95.
15. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747–54.
16. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396–406.
17. Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 2013;65:2499–512.
18. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202–9.
19. Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM, Suijlekom-Smit LW, Kamphuis SS, et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 2009;61:46–51.
20. Halle F, Prieur AM. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol 1991;9:297–302.
21. Speckmaier M, Findeisen J, Woo P, Hall A, Sills JA, Price T, et al. Low-dose methotrexate in systemic onset juvenile chronic arthritis. Clin Exp Rheumatol 1989;7:647–50.
22. Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43:1849–57.
23. Beukelman T. Treatment advances in systemic juvenile idiopathic arthritis. F1000Prime Rep 2014;6:21.
24. Minden K, Niewerth M, Listing J, Zink A, German Study Group of Pediatric Rheumatologists. Health care provision in pediatric rheumatology in Germany: national rheumatologic database. J Rheumatol 2002;29:622–8.
25. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998;25:1991–4.
26. Foeldvari I, Ruperto N, Dressler F, Hafner R, Kuster RM, Michels H, et al. The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001;19 Suppl 23:S71–5.
27. Consolaro A, Negro G, Chiara Gallo M, Bracciolini G, Ferrari C, Schiappapietra B, et al. Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. Arthritis Care Res (Hoboken) 2014;66:1703–9.
28. Kurth BM, Schaffrath Rosario A. The prevalence of overweight and obese children and adolescents living in Germany: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007;50:736–43. In German.
29. Breslow NE, Clayton DG. Approximate inference in generalized linear mixed models. J Am Stat Assoc 1993;88:9–25.
30. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963–74.
31. Molenberghs G, Kenward MG. Missing data in clinical studies. Hoboken (NJ): John Wiley & Sons; 2007.
32. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550–60.
33. Bertilsson L, Andersson-Gare B, Fasth A, Petersson IF, Forsblad-D'elia H. Disease course, outcome, and predictors of outcome in a population-based juvenile chronic arthritis cohort followed for 17 years. J Rheumatol 2013;40:715–24.
34. Svantesson H, Akesson A, Eberhardt K, Elborgh R. Prognosis in juvenile rheumatoid arthritis with systemic onset: a follow-up study. Scand J Rheumatol 1983;12:139–44.
35. Wulffraat NM, Brinkman D, Ferster A, Opperman J, ten Cate R, Wedderburn L, et al. Long-term follow-up of autologous stem cell transplantation for refractory juvenile idiopathic arthritis. Bone Marrow Transplant 2003;32 Suppl 1:S61–4.
36. Hafner R, Truckenbrodt H. Course and prognosis of systemic juvenile chronic arthritis: retrospective study of 187 patients. Klin Padiatr 1986;198:401–7. In German.
37. Nigrovic PA, White PH. Care of the adult with juvenile rheumatoid arthritis. Arthritis Rheum 2006;55:208–16.
38. Oen K, Duffy CM, Tse SM, Ramsey S, Ellsworth J, Chedeville G, et al. Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care Res (Hoboken) 2010;62:527–36.
39. Prieur AM, Bremard-Oury C, Griscelli C, Mozziconacci P. Prognosis of the systemic forms of juvenile chronic arthritis: apropos of 100 cases. Arch Fr Pediatr 1984;41:91–7. In French.
40. Russo RA, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 2009;36:1078–82.
41. Russo RA, Katsicas MM. Patients with very early-onset systemic juvenile idiopathic arthritis exhibit more inflammatory features and a worse outcome. J Rheumatol 2013;40:329–34.
42. Otten MH, Anink J, Spronk S, van Suijlekom-Smit LW. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann Rheum Dis 2013;72:1806–12.
43. Woerner A, Uettwiller F, Melki I, Mouy R, Wouters C, Bader-Meunier B, et al. Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open 2015;1:e000036.
44. Behrens EM. Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell? Autoimmun Rev 2008;7:305–8.
45. Simon D, Fernando C, Czernichow P, Prieur AM. Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. J Rheumatol 2002;29:1296–300.
46. Bechtold S, Simon D. Growth abnormalities in children and adolescents with juvenile idiopathic arthritis. Rheumatol Int 2014;34:1483–8.
47. Bechtold S, Roth J. Natural history of growth and body composition in juvenile idiopathic arthritis. Horm Res 2009;72 Suppl 1:13–9.
48. Bechtold S, Ripperger P, Hafner R, Said E, Schwarz HP. Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. J Pediatr 2003;143:512–9.
49. De Benedetti F, Brunner H, Ruperto N, Schneider R, Xavier R, Allen R, et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol 2015;67:840–8.
50. McErlane F, Beresford MW, Baildam EM, Thomson W, Hyrich KL. Recent developments in disease activity indices and outcome measures for juvenile idiopathic arthritis. Rheumatology (Oxford) 2013;52:1941–51.